Key Points
- BioNTech CEO Ugur Sahin sold 32,000 shares at an average of $98.12, generating approximately $3.14 million. The transaction was conducted under a pre-arranged Rule 10b5-1 trading plan, leaving him with 214,209 shares.
- Sahin has made a series of additional stock sales throughout September, indicating substantial ongoing insider selling.
- BioNTech shares opened at $98.30, while the company reported weaker quarterly results: a $2.53 per-share loss and revenue of $122.31 million, down 59.5% year over year. Analysts nevertheless maintain a “Moderate Buy” consensus with a $126 price target.
BioNTech SE Sponsored ADR (NASDAQ:BNTX - Get Free Report) CEO Ugur Sahin sold 32,000 shares of the company's stock in a transaction that occurred on Wednesday, September 30th. The stock was sold at an average price of $98.12, for a total value of $3,139,840.00. Following the transaction, the chief executive officer directly owned 214,209 shares of the company's stock, valued at approximately $21,018,187.08. The trade was a 13.00% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Ugur Sahin also recently made the following trade(s):
- On Monday, September 28th, Ugur Sahin sold 34,000 shares of BioNTech stock. The shares were sold at an average price of $98.47, for a total value of $3,347,980.00.
- On Friday, September 25th, Ugur Sahin sold 27,000 shares of BioNTech stock. The shares were sold at an average price of $98.69, for a total transaction of $2,664,630.00.
- On Thursday, September 24th, Ugur Sahin sold 39,000 shares of BioNTech stock. The stock was sold at an average price of $98.99, for a total transaction of $3,860,610.00.
- On Wednesday, September 23rd, Ugur Sahin sold 30,000 shares of BioNTech stock. The stock was sold at an average price of $99.40, for a total transaction of $2,982,000.00.
- On Tuesday, September 22nd, Ugur Sahin sold 46,000 shares of BioNTech stock. The shares were sold at an average price of $100.72, for a total transaction of $4,633,120.00.
- On Monday, September 21st, Ugur Sahin sold 33,000 shares of BioNTech stock. The shares were sold at an average price of $97.81, for a total transaction of $3,227,730.00.
- On Friday, September 18th, Ugur Sahin sold 30,000 shares of BioNTech stock. The shares were sold at an average price of $96.22, for a total transaction of $2,886,600.00.
- On Thursday, September 17th, Ugur Sahin sold 34,000 shares of BioNTech stock. The stock was sold at an average price of $98.60, for a total transaction of $3,352,400.00.
- On Wednesday, September 16th, Ugur Sahin sold 15,000 shares of BioNTech stock. The stock was sold at an average price of $96.09, for a total transaction of $1,441,350.00.
- On Tuesday, September 15th, Ugur Sahin sold 34,000 shares of BioNTech stock. The stock was sold at an average price of $96.49, for a total transaction of $3,280,660.00.
BioNTech Trading Down 0.3%
Shares of BioNTech stock opened at $98.30 on Thursday. The company has a current ratio of 7.85, a quick ratio of 7.80 and a debt-to-equity ratio of 0.01. BioNTech SE Sponsored ADR has a twelve month low of $79.52 and a twelve month high of $124.00. The firm has a market capitalization of $24.86 billion, a PE ratio of -12.55 and a beta of 1.29. The firm's 50-day moving average price is $98.56 and its 200 day moving average price is $94.96.
BioNTech (NASDAQ:BNTX - Get Free Report) last posted its quarterly earnings data on Tuesday, August 4th. The company reported ($2.53) EPS for the quarter, missing the consensus estimate of ($2.40) by ($0.13). BioNTech had a negative return on equity of 6.86% and a negative net margin of 63.54%.The firm had revenue of $122.31 million for the quarter, compared to analysts' expectations of $180.18 million. During the same quarter last year, the firm posted ($1.60) earnings per share. BioNTech's quarterly revenue was down 59.5% on a year-over-year basis. On average, sell-side analysts predict that BioNTech SE Sponsored ADR will post -6.37 EPS for the current fiscal year.
Institutional Investors Weigh In On BioNTech
Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Flossbach Von Storch SE purchased a new position in BioNTech during the second quarter worth approximately $207,142,000. Bank of America Corp DE grew its holdings in BioNTech by 22.6% in the 1st quarter. Bank of America Corp DE now owns 903,029 shares of the company's stock valued at $80,261,000 after buying an additional 166,432 shares in the last quarter. First Trust Advisors LP grew its holdings in BioNTech by 116.0% in the 1st quarter. First Trust Advisors LP now owns 839,991 shares of the company's stock valued at $74,658,000 after buying an additional 451,124 shares in the last quarter. Assenagon Asset Management S.A. acquired a new stake in shares of BioNTech in the 2nd quarter worth $39,385,000. Finally, CenterBook Partners LP increased its stake in shares of BioNTech by 27.3% in the 4th quarter. CenterBook Partners LP now owns 236,175 shares of the company's stock worth $22,484,000 after acquiring an additional 50,684 shares during the last quarter. Institutional investors and hedge funds own 15.52% of the company's stock.
Analyst Upgrades and Downgrades
Several research firms recently commented on BNTX. UBS Group reissued a "buy" rating on shares of BioNTech in a research note on Wednesday, September 16th. Wall Street Zen cut shares of BioNTech from a "hold" rating to a "sell" rating in a research note on Saturday, August 8th. Canaccord Genuity Group dropped their target price on shares of BioNTech from $142.00 to $136.00 and set a "buy" rating for the company in a report on Monday, August 31st. Citigroup reduced their target price on shares of BioNTech from $130.00 to $125.00 and set a "buy" rating for the company in a research report on Wednesday, August 5th. Finally, Morgan Stanley decreased their price target on shares of BioNTech from $126.00 to $119.00 and set an "overweight" rating on the stock in a research note on Wednesday, July 8th. One research analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating, five have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $126.00.
View Our Latest Analysis on BNTX
BioNTech Company Profile
(
Get Free Report)
BioNTech SE is a biotechnology company headquartered in Mainz, Germany, focused on developing therapies and vaccines for cancer and other serious diseases. The company's research platform includes messenger RNA (mRNA), individualized cancer vaccines, immune-modulating therapies, cell therapies, and protein-based therapeutics.
BioNTech is best known for developing the Comirnaty COVID-19 vaccine in collaboration with Pfizer. Comirnaty uses mRNA technology to help stimulate an immune response against COVID-19 and has been distributed in markets around the world.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
